SCHEMBL2586955

SCHEMBL2586955

COC(=O)c1csc(-c2cnn(COCC[Si](C)(C)C)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.39
ACHE P22303 1/20 0.39
HPGDS O60760 2/20 0.36
RAB9A P51151 4/20 0.36
GAA P10253 2/20 0.36
PIM1 P11309 1/20 0.36
MAP3K5 Q99683 2/20 0.35
RET P07949 1/20 0.35
CDK2 P24941 1/20 0.35
GSK3B P49841 1/20 0.35
MERTK Q12866 1/20 0.35
PRKAA1 Q13131 1/20 0.35
ROCK1 Q13464 1/20 0.35
CLK2 P49760 1/20 0.35
LRRK2 Q5S007 1/20 0.35
NPC1 O15118 2/20 0.35
CLK1 P49759 1/20 0.35
ALDH1A1 P00352 2/20 0.34
POLB P06746 1/20 0.34
TLR7 Q9NYK1 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2590821 0.89 ALDH1A1 (0.45) ACHEHPGDSPIM1CLK2LRRK2
SCHEMBL27229211 0.82 CLK2 (0.42) PIM1MAP3K5RETCDK2GSK3B
SCHEMBL27229246 0.81 PIM1 (0.40) PIM1MAP3K5RETCDK2GSK3B
SCHEMBL27229315 0.78 CLK2 (0.68) PIM1MAP3K5RETCDK2GSK3B
SCHEMBL27229368 0.78 CLK2 (0.52) RAB9APIM1MAP3K5RETCDK2
SCHEMBL27229337 0.78 PIM1 (0.42) PIM1MAP3K5RETCDK2GSK3B
SCHEMBL23165789 0.78 MAPT (0.38) RAB9ANPC1ALDH1A1
SCHEMBL27229297 0.77 CLK2 (0.47) PIM1MAP3K5RETCDK2GSK3B
SCHEMBL20271394 0.76 HPGD (0.39) ACHENPC1ALDH1A1DGAT1
SCHEMBL27229383 0.76 CLK2 (0.50) PIM1MAP3K5RETCDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174679-A1 HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-05-30 US disclosed
EP-2563358-A1 INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) Merck Sharp & Dohme Corp. (US) 2013-03-06 EP disclosed
US-20130053382-A1 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) PALIWAL SUNIL (US) 2013-02-28 US disclosed
US-20130053382-A1 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) PALIWAL SUNIL (US) 2013-02-28 US disclosed
WO-2011137219-A1 INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) SCHERING CORPORATION (US) 2011-11-03 WO disclosed
WO-2011137219-A1 INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) SCHERING CORPORATION (US) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053382-A1 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) PDK1, PDPK1, PDK3 MAOA 4588/4885ACHE 4501/4885HPGDS 1838/4885
US-20240174679-A1 HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF LRRK2, CLK2, BRSK2 MAOA 1116/4885ACHE 3143/4885HPGDS 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.